세계의 만성 림프구성 백혈병 치료제 시장(2024-2028년)

The chronic lymphocytic leukemia therapeutics market is forecasted to grow by USD 2.92 bn during 2023-2028, accelerating at a CAGR of 8.82% during the forecast period. The report on the chronic lymphocytic leukemia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing research grants for different blood cancers, the increasing prevalence of chronic lymphocytic leukemia, and the growing geriatric population.

Technavio's chronic lymphocytic leukemia therapeutics market is segmented as below:

By Route Of Administration

• Parenteral
• Oral

By Therapy

• Chemotherapy
• Targeted
• Others

By Geography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the special drug designations for chronic lymphocytic leukemia therapeutics as one of the prime reasons driving the chronic lymphocytic leukemia therapeutics market growth during the next few years. Also, the rise in R&D activities related to innovative chronic lymphocytic leukemia therapeutics and increased use of predictive biomarkers for diagnosing chronic lymphocytic leukemia will lead to sizable demand in the market.

The report on the chronic lymphocytic leukemia therapeutics market covers the following areas:

• Chronic lymphocytic leukemia therapeutics market sizing
• Chronic lymphocytic leukemia therapeutics market forecast
• Chronic lymphocytic leukemia therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic lymphocytic leukemia therapeutics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., R2T BIOPHARMA INC, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the chronic lymphocytic leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global chronic lymphocytic leukemia therapeutics market 2018 - 2022
• 4.2 Route Of Administration Segment Analysis 2018 - 2022
• 4.3 Therapy Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Route of Administration

• 6.1 Market segments
• 6.2 Comparison by Route of Administration
• 6.3 Parenteral - Market size and forecast 2023-2028
• 6.4 Oral - Market size and forecast 2023-2028
• 6.5 Market opportunity by Route of Administration

7 Market Segmentation by Therapy

• 7.1 Market segments
• 7.2 Comparison by Therapy
• 7.3 Chemotherapy - Market size and forecast 2023-2028
• 7.4 Targeted - Market size and forecast 2023-2028
• 7.5 Others - Market size and forecast 2023-2028
• 7.6 Market opportunity by Therapy

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 Germany - Market size and forecast 2023-2028
• 9.9 China - Market size and forecast 2023-2028
• 9.10 Japan - Market size and forecast 2023-2028
• 9.11 UK - Market size and forecast 2023-2028
• 9.12 Market opportunity by geography

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 AbbVie Inc.
• 12.4 Amgen Inc.
• 12.5 AstraZeneca PLC
• 12.6 Biogen Inc.
• 12.7 Bristol-Myers Squibb Company
• 12.8 F. Hoffmann La Roche Ltd.
• 12.9 Gilead Sciences Inc.
• 12.10 GlaxoSmithKline Plc
• 12.11 Novartis AG
• 12.12 Pfizer Inc.
• 12.13 R2T BIOPHARMA INC
• 12.14 Sanofi SA
• 12.15 Takeda Pharmaceutical Co. Ltd.
• 12.16 Teva Pharmaceutical Industries Ltd.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations